Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT

Park, Bok-Nam; Kim, Jang-Hee; Lee, Kwanjae; An, Young‐Sil

doi:10.1007/s00330-014-3549-3

Cited by 18 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In PD, BMSCs have the ability to regenerate damaged neurons [163,164]. Moreover, BMSCs can improve the dopamine transporter binding activity, which results in the recovery and protection of dopaminergic neurons [165]. Several clinical trials are conducted while using BMSCs on PD patients (NCT02611167, NCT01446614, NCT00976430).…”

Section: Bmscs Involved In the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Chu

Phuong

Tien

et al. 2020

IJMS

125

View full text Add to dashboard Cite

Bone marrow mesenchymal stem/stromal cells (BMSCs), which are known as multipotent cells, are widely used in the treatment of various diseases via their self-renewable, differentiation, and immunomodulatory properties. In-vitro and in-vivo studies have supported the understanding mechanisms, safety, and efficacy of BMSCs therapy in clinical applications. The number of clinical trials in phase I/II is accelerating; however, they are limited in the size of subjects, regulations, and standards for the preparation and transportation and administration of BMSCs, leading to inconsistency in the input and outcome of the therapy. Based on the International Society for Cellular Therapy guidelines, the characterization, isolation, cultivation, differentiation, and applications can be optimized and standardized, which are compliant with good manufacturing practice requirements to produce clinical-grade preparation of BMSCs. This review highlights and updates on the progress of production, as well as provides further challenges in the studies of BMSCs, for the approval of BMSCs widely in clinical application.

show abstract

Section: Bmscs Involved In the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Chu

Phuong

Tien

et al. 2020

IJMS

125

View full text Add to dashboard Cite

show abstract

“…MSCs have the ability to migrate to injury sites and promote repair, which makes them compelling candidates for systemic administration. Systemic administration of MSCs has been shown to be effective using BM-derived MSCs [124][125][126][127][128][129][130] and AD-derived MSCs 126 . In many of these studies, behavioral improvement, neuroprotective effects, and neurogeneration were observed.…”

Section: Route Of Delivery and Other Variabilitiesmentioning

confidence: 99%

Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson’s disease

2020

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies, which gives rise to motor and non-motor symptoms. Unfortunately, current therapeutic strategies for PD merely treat the symptoms of the disease, only temporarily improve the patients’ quality of life, and are not sufficient for completely alleviating the symptoms. Therefore, cell-based therapies have emerged as a novel promising therapeutic approach in PD treatment. Mesenchymal stem/stromal cells (MSCs) have arisen as a leading contender for cell sources due to their regenerative and immunomodulatory capabilities, limited ethical concerns, and low risk of tumor formation. Although several studies have shown that MSCs have the potential to mitigate the neurodegenerative pathology of PD, variabilities in preclinical and clinical trials have resulted in inconsistent therapeutic outcomes. In this review, we strive to highlight the sources of variability in studies using MSCs in PD therapy, including MSC sources, the use of autologous or allogenic MSCs, dose, delivery methods, patient factors, and measures of clinical outcome. Available evidence indicates that while the use of MSCs in PD has largely been promising, conditions need to be standardized so that studies can be effectively compared with one another and experimental designs can be improved upon, such that this body of science can continue to move forward.

show abstract

“…The ideal material is visible under detecting instruments without the requirement for invasive methods [ 44 , 45 ]. Some researchers are exploring the utility of optogenetics, F-18 FP-CIT PET, and MION-Rh to measure the therapeutic effect of stem cells in PD [ 17 , 25 , 46 ]. These technologies can integrate the transplantation, cell viability, animal behavior, and histopathological evaluation to enable the identification of mechanisms that drive functional recovery.…”

Section: Discussionmentioning

confidence: 99%

The Preclinical Research Progress of Stem Cells Therapy in Parkinson’s Disease

Zhang

Wang

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Parkinson's disease (PD) is a type of degenerative disorder of the basal ganglia, causing tremor at rest, muscle rigidity hypokinesia, and dementia. The effectiveness of drug treatments gradually diminishes because the conversion to dopamine within the brain is increasingly disrupted by the progressive degeneration of the dopaminergic terminals. After long-term treatment, most patients with PD suffer from disability that cannot be satisfactorily controlled. To solve these issues, stem cells have recently been used for cell therapy of PD. In this review, the characteristics of different stem cells and their therapeutic effects on PD treatment will be discussed.

show abstract

Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson’s disease: small animal positron emission tomography study with F-18 FP-CIT

Cited by 18 publications

References 44 publications

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson’s disease

The Preclinical Research Progress of Stem Cells Therapy in Parkinson’s Disease

Contact Info

Product

Resources

About